● Pre-treatment NLR and PLR do not predict survival in GBM.
● Baseline inflammatory indices are not independent prognostic markers.
● Only single measurements limit the utility of blood-based biomarkers.
● Survival in GBM is not driven by static peripheral immune profiles.
● Dynamic immune monitoring is needed for better risk stratification.